Takeda Industry Symposium

Let’s get real: Modern management of RRMM in older patients

Friday, May 12, 2023
08:30–09:30 CEST

Professor Philippe Moreau

Dr Hira Mian

Dr Paul Richardson


Welcome and introductions
Session 1:
Closing the gap: Unmet needs in older patients with RRMM
Session 2:
Treatment approaches for older patients with RRMM
Session 3:
Interactive ‘How I treat’ case studies
Session 4:
What’s on the horizon for the treatment of older patients with RRMM?
Q&A and closing remarks

Principal objective

Our goal is to educate on the treatment of multiple myeloma, especially with respect to treatment options and, in particular, treatment in elderly fit and/or frail populations. Other patient populations include the indolent/biochemical relapsed patients and patients who have already been exposed to lenalidomide or daratumumab in prior lines of treatment.

Symposium learning objectives

Following attendance of this symposium, participants should be able to:

  • Describe the need for communicating real-world clinical expertise in managing MM in older and/or frail patients who are not adequately represented in clinical trials – Philippe Moreau
  • Identify factors that should be considered when selecting a treatment for older and/or frail patients with MM – Hira Mian
  • State when frailty should be measured – Hira Mian
  • Recall data for emerging therapies for RRMM – Paul Richardson